The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
The transaction is valued at $1.40 billion, which is subject to customary approvals and is expected to take place around the end of 2024, according to a press release ...
Woodland Biofuels Inc. (Toronto, Ont., Canada) announced a planned $1.35-billion investment at the Port of South Louisiana to establish what is said to be ...